Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
AssigneeThe Johns Hopkins University
InventorsJennifer E. Van Eyk, Allen Dale Everett, Zhicheng Jin
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injury or neurodegeneration. In one embodiment, a method for diagnosing brain injury in a patient comprises the steps of (a) obtaining a sample from the patient; (b) determining the ratio of citrullinated to unmodified arginine residues at one or more arginine residues of one or more brain injury biomarker proteins; and (c) correlating the ratio to a patient having brain injury or to a patient not having brain injury, thereby providing the diagnosis.
Claims16
A method for detecting citrullinated brain injury biomarker proteins in a sample from a subject having or suspected of having brain injury, the method comprising:
- detecting in the subject's sample citrullinated arginine residues in citrullinated brain injury biomarker protein glial fibrillary acidic protein (GFAP) and/or citrullinated brain injury biomarker protein myelin basic protein (MBP) by detecting the citrullinated arginine residues in said citrullinated biomarker proteins using a detection method selected from mass spectrometry, immunoassay, electrochemical luminescent assay, electrochemical voltametry, electrochemical amperometry, atomic force microscopy, radio frequency multipolar resonance spectroscopy, confocal microscopy, non-confocal microscopy, fluorescence optical detection, luminescence optical detection, chemiluminescence optical detection, absorbance optical detection, reflectance optical detection, transmittance optical detection, birefringence optical detection, refractive index detection, surface plasmon resonance, ellipsometry, resonant mirror detection, grating coupler waveguide detection, or interferometry;
- thereby detecting citrullinated brain injury biomarker proteins in the subject's sample.
A method for detecting autoantibodies against a citrullinated brain injury biomarker protein in a sample from a subject, the method comprising the steps of:
- (a) contacting a biological sample obtained from the subject with citrullinated brain injury biomarker protein glial fibrillary acidic protein (GFAP) and/or citrullinated brain injury biomarker protein myelin basic protein (MBP);
- and
- (b) detecting the binding of the citrullinated GFAP and/or citrullinated MBP brain injury biomarker proteins to autoantibodies in the sample which are specific for the citrullinated brain injury biomarker proteins, said detection of binding being indicative of the presence of citrullinated brain injury biomarker protein autoantibodies.
Dependencies are inferred from the claim text.